Search research articles
Contact Us
Filters
Showing results (41-50 of 137) with videos related to
Page
of 14
Sort By:
Biopharmaceutics & Drug Disposition
|
April 22, 2018
Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis
Mysore S Anil Kumar, Kim Papp, Ryo Tainaka, et al.
Journal of Cutaneous Medicine and Surgery
|
May 16, 2013
Understanding and assessing potential serious adverse events: a practical approach to understanding the benefits and harm of psoriasis treatments
Kim Papp, Lyn Guenther, Neil Shear, et al.
Journal of Cutaneous Medicine and Surgery
|
December 29, 2011
Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations
Lorne Albrecht, Marc Bourcier, John Ashkenas, et al.
Cutis
|
February 27, 2010
Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis
Yves Poulin, Kim Papp, Robert Bissonnette, et al.
European Journal of Dermatology : EJD
|
August 25, 2010
Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body
Jean-Paul Ortonne, Kirsten Lykke Noerrelund, Kim Papp, et al.
Journal of the American Academy of Dermatology
|
February 18, 2010
A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis
Robert Bissonnette, Kim Papp, Catherine Maari, et al.
BMC Dermatology
|
February 28, 2007
Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
Michelle A Lowes, Francesca Chamian, Maria V Abello, et al.
American Journal of Clinical Dermatology
|
August 13, 2011
The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials
Craig Leonardi, Kim Papp, Bruce Strober, et al.
Archives of Dermatological Research
|
May 28, 2009
Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab
Robert Bissonnette, Richard G Langley, Kim Papp, et al.
Rheumatology (Oxford, England)
|
July 8, 2022
Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1
Lars Erik Kristensen, Ahmed M Soliman, Kim Papp, et al.
Page
of 14
Search research articles
Search
Showing results (41-50 of 137) with videos related to
Sort By:
Page
of 14
Biopharmaceutics & Drug Disposition
|
April 22, 2018
Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis
Mysore S Anil Kumar, Kim Papp, Ryo Tainaka, et al.
Journal of Cutaneous Medicine and Surgery
|
May 16, 2013
Understanding and assessing potential serious adverse events: a practical approach to understanding the benefits and harm of psoriasis treatments
Kim Papp, Lyn Guenther, Neil Shear, et al.
Journal of Cutaneous Medicine and Surgery
|
December 29, 2011
Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations
Lorne Albrecht, Marc Bourcier, John Ashkenas, et al.
Cutis
|
February 27, 2010
Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis
Yves Poulin, Kim Papp, Robert Bissonnette, et al.
European Journal of Dermatology : EJD
|
August 25, 2010
Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body
Jean-Paul Ortonne, Kirsten Lykke Noerrelund, Kim Papp, et al.
Journal of the American Academy of Dermatology
|
February 18, 2010
A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis
Robert Bissonnette, Kim Papp, Catherine Maari, et al.
BMC Dermatology
|
February 28, 2007
Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
Michelle A Lowes, Francesca Chamian, Maria V Abello, et al.
American Journal of Clinical Dermatology
|
August 13, 2011
The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials
Craig Leonardi, Kim Papp, Bruce Strober, et al.
Archives of Dermatological Research
|
May 28, 2009
Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab
Robert Bissonnette, Richard G Langley, Kim Papp, et al.
Rheumatology (Oxford, England)
|
July 8, 2022
Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1
Lars Erik Kristensen, Ahmed M Soliman, Kim Papp, et al.
Page
of 14